144 related articles for article (PubMed ID: 7607905)
1. [Isolated extremity perfusion with tumor necrosis factor and melphalan.An option for treatment of satellite or in transit metastasis of malignant melanoma].
Schlag PM; Kettelhack C
Hautarzt; 1995 May; 46(5):361-2. PubMed ID: 7607905
[No Abstract] [Full Text] [Related]
2. [Isolated hyperthermic perfusion of extremities in malignant melanoma with melphalan and tumor necrosis factor].
Kettelhack C; Hohenberger P; Schlag PM
Langenbecks Arch Chir Suppl Kongressbd; 1996; 113():127-9. PubMed ID: 9101810
[TBL] [Abstract][Full Text] [Related]
3. Isolated limb perfusion for melanoma in-transit metastases: developments in recent years and the role of tumor necrosis factor alpha.
Deroose JP; Eggermont AM; van Geel AN; Verhoef C
Curr Opin Oncol; 2011 Mar; 23(2):183-8. PubMed ID: 21150602
[TBL] [Abstract][Full Text] [Related]
4. Palliation of regional symptoms of advanced extremity melanoma by isolated limb perfusion with melphalan and high-dose tumor necrosis factor.
Fraker DL; Alexander HR; Andrich M; Rosenberg SA
Cancer J Sci Am; 1995; 1(2):122-30. PubMed ID: 9166465
[TBL] [Abstract][Full Text] [Related]
5. Treatment of in-transit metastases from cutaneous melanoma by isolation perfusion with tumour necrosis factor-alpha (TNF-alpha), melphalan and interferon-gamma (IFN-gamma). Dose-finding experience at the National Cancer Institute of Milan.
Vaglini M; Santinami M; Manzi R; Inglese MG; Santoro N; Persiani L; Belli F
Melanoma Res; 1994 Mar; 4 Suppl 1():35-8. PubMed ID: 8038594
[TBL] [Abstract][Full Text] [Related]
6. Hyperthermic isolated limb perfusion with tumor necrosis factor alone for melanoma.
Posner MC; Lienard D; Lejeune FJ; Rosenfelder D; Kirkwood J
Cancer J Sci Am; 1995; 1(4):274-80. PubMed ID: 9166488
[TBL] [Abstract][Full Text] [Related]
7. Hyperthermic isolation limb perfusion with TNFalpha in the treatment of in-transit melanoma metastasis.
Di Filippo F; Rossi CR; Santinami M; Cavaliere F; Garinei R; Anzà M; Perri P; Botti C; Di Angelo P; Pasqualoni R; Di Filippo S
In Vivo; 2006; 20(6A):739-42. PubMed ID: 17203758
[TBL] [Abstract][Full Text] [Related]
8. Is there any reason to delay introduction of tumor necrosis factor in the management of in-transit metastasis of unresectable melanoma?
Garrido-Laguna I; Ponz M; Espinós J
J Clin Oncol; 2007 Mar; 25(9):1149; author reply 1149-51. PubMed ID: 17369585
[No Abstract] [Full Text] [Related]
9. Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion.
Noorda EM; Vrouenraets BC; Nieweg OE; van Geel AN; Eggermont AM; Kroon BB
Eur J Surg Oncol; 2006 Apr; 32(3):318-24. PubMed ID: 16412605
[TBL] [Abstract][Full Text] [Related]
10. Complete response of melanoma-in-transit metastasis after isolated limb perfusion with tumor necrosis factor alpha and melphalan without massive tumor necrosis: a clinical and histopathological study of the delayed-type reaction pattern.
Nooijen PT; Eggermont AM; Schalkwijk L; Henzen-Logmans S; de Waal RM; Ruiter DJ
Cancer Res; 1998 Nov; 58(21):4880-7. PubMed ID: 9809994
[TBL] [Abstract][Full Text] [Related]
11. Isolated limb perfusion for unresectable melanoma of the extremities.
Noorda EM; Vrouenraets BC; Nieweg OE; van Geel BN; Eggermont AM; Kroon BB
Arch Surg; 2004 Nov; 139(11):1237-42. PubMed ID: 15545572
[TBL] [Abstract][Full Text] [Related]
12. Palliation of regional symptoms of advanced extremity melanoma by isolated limb perfusion.
Coit DG
Cancer J Sci Am; 1995; 1(2):104-5. PubMed ID: 9166460
[No Abstract] [Full Text] [Related]
13. Isolated limb perfusion with high-dose tumor necrosis factor for extremity melanoma and sarcoma.
Fraker DL; Alexander HR
Important Adv Oncol; 1994; ():179-92. PubMed ID: 8206489
[No Abstract] [Full Text] [Related]
14. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020.
Cornett WR; McCall LM; Petersen RP; Ross MI; Briele HA; Noyes RD; Sussman JJ; Kraybill WG; Kane JM; Alexander HR; Lee JE; Mansfield PF; Pingpank JF; Winchester DJ; White RL; Chadaram V; Herndon JE; Fraker DL; Tyler DS;
J Clin Oncol; 2006 Sep; 24(25):4196-201. PubMed ID: 16943537
[TBL] [Abstract][Full Text] [Related]
15. Merkel cell carcinoma: an unusual indication for isolated limb perfusion.
Ponte P; Moniz JV; Farricha V; Weinholtz JB
Dermatol Online J; 2008 Jul; 14(7):6. PubMed ID: 18718190
[TBL] [Abstract][Full Text] [Related]
16. Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advanced melanoma and soft-tissue sarcoma.
Hayes AJ; Neuhaus SJ; Clark MA; Thomas JM
Ann Surg Oncol; 2007 Jan; 14(1):230-8. PubMed ID: 17066234
[TBL] [Abstract][Full Text] [Related]
17. Treatment of melanoma metastases in a limb by isolated limb perfusion and isolated limb infusion.
Testori A; Verhoef C; Kroon HM; Pennacchioli E; Faries MB; Eggermont AM; Thompson JF
J Surg Oncol; 2011 Sep; 104(4):397-404. PubMed ID: 21858835
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure.
Grünhagen DJ; van Etten B; Brunstein F; Graveland WJ; van Geel AN; de Wilt JH; Eggermont AM
Ann Surg Oncol; 2005 Aug; 12(8):609-15. PubMed ID: 15968498
[TBL] [Abstract][Full Text] [Related]
19. [O2 utilization during hyperthermic extremity perfusion with rhTNF alpha and melphalan].
Haier J; Hohenberger P; Beck K; Schlag PM
Langenbecks Arch Chir; 1997; 382(3):128-33. PubMed ID: 9324610
[TBL] [Abstract][Full Text] [Related]
20. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
